Physician profile
Mohammed Wael W Al-Ameri
NPI 1861591794
$12,450.37
in general payments reported to CMS, 2019-2025
41 companies · $2,598 in 2025
The $2,598 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,149 · 2020: $962 · 2021: $1,393 · 2022: $1,875 · 2023: $2,337 · 2024: $2,136 · 2025: $2,598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,973 · Education: $97.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,972.78 |
| Education | $97.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,666.23 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $2,116.44 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,121.66 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Genzyme Corporation | $1,082.42 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $593.34 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Regeneron Healthcare Solutions, INC. | $512.01 | 2019-2025 | Dupixent |
| Insmed, INC. | $502.54 | 2021-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $455.25 | 2019-2024 | Yupelri |
| United Therapeutics Corporation | $424.12 | 2021-2024 | Tyvaso |
| Harmony Biosciences LLC | $408.19 | 2022-2024 | Wakix |
| Grifols USA, LLC | $331.14 | 2019-2025 | Prolastin-C Liquid |
| Axsome Therapeutics, INC. | $236.13 | 2023-2025 | Sunosi |
| Electromed, INC. | $234.81 | 2019-2025 | Smartvest |
| Abbvie INC. | $155.46 | 2023 | Qulipta, Ubrelvy, Avycaz |
| Sunovion Pharmaceuticals INC. | $154.01 | 2019-2020 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $146.06 | 2025 | Yupelri |
| Pulmonx Corporation | $111.02 | 2021-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Novo Nordisk INC | $107.10 | 2025 | Wegovy |
| Mallinckrodt Hospital Products INC. | $101.16 | 2020-2023 | Acthar |
| Resmed Corp | $97.46 | 2022-2025 | |
| Inogen, INC. | $96.17 | 2022-2024 | Inogen |
| Advanced Respiratory, INC | $86.54 | 2019-2021 | |
| Amgen INC. | $81.08 | 2019 | |
| Genentech USA, INC. | $65.10 | 2022-2024 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $62.08 | 2021-2023 | Glassia |
| Jazz Pharmaceuticals INC. | $57.95 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $44.03 | 2021 | |
| Novartis Pharmaceuticals Corporation | $43.94 | 2019 | |
| Circassia INC. | $42.58 | 2019 | |
| Janssen Pharmaceuticals, INC | $42.15 | 2022-2024 | Xarelto |
| Mallinckrodt Enterprises LLC | $41.69 | 2019 | |
| Merck Sharp & Dohme LLC | $38.55 | 2023-2024 | Keytruda |
| Philips North America LLC | $37.28 | 2020 | |
| Penumbra, INC. | $31.46 | 2021-2022 | |
| Vapotherm INC | $27.42 | 2022 | |
| Covis Pharma Gmbh | $19.16 | 2022 | |
| Edwards Lifesciences Corporation | $17.21 | 2025 | Sapien 3 Ultra Resilia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.08 | 2019 | |
| Azurity Pharmaceuticals, INC. | $16.34 | 2023 | Horizant |
| Ani Pharmaceuticals, INC. | $13.14 | 2024 | Purified Cortrophin Gel |
| 3b Medical, INC. | $12.87 | 2024 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Wael Al-Ameri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.